Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >


Add CYDY Price Alert      Hide Sticky   Hide Intro
Moderator: JPG77, BostonSportsNut, gestalt2, Bulldog88, BlueHorseshoe13
Search This Board: 
Last Post: 8/22/2017 8:36:33 PM - Followers: 144 - Board type: Free - Posts Today: 56

CytoDyn Inc. (CYDY) is a Vancouver, Washington-based biotechnology company engaged in the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection.

Monoclonal antibodies – soluble proteins produced by the body in response to infections from bacteria, viruses and other pathogens – have become one of the fastest expanding opportunities in the biotech/pharma sector. CytoDyn's lead drug candidate is PRO 140, one of the leading monoclonal antibodies under development for HIV infection.

CytoDyn operates under the guidance of a highly qualified management team and advisors with experience in a wide range of complementary skillsets, including business development, mechanical engineering, life sciences and biotech, manufacturing and clinical development, IP asset development, biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs and more.

Additionally, CytoDyn has established relationships with world-class HIV experts who advise on the company's trial designs.

Investment Highlights

  • Positioning in two multi-billion dollar markets
    Have initiated two Phase 3 trials for HIV and one Phase 2 for non-HIV Graft vs. Host Disease (GvHD)
    Primary endpoint results for a pivotal Phase 3 is expected in first quarter 2017


PRO 140

CytoDyn's lead product candidate, PRO 140, belongs to a new class of HIV/AIDS therapeutics intended to protect healthy cells from viral infection. The PRO 140 antibody appears to be a powerful antiviral agent leading to potentially minimum side effects or toxicity and less frequent dosing requirements, as compared to daily drug therapies currently in use.

PRO 140 Highlights:

  • Candidate has been used in more than 200 HIV-infected patients in placebo-controlled and open-label FDA-approved clinical trials;
    Was the subject of seven clinical trials, each demonstrating efficacy by significantly reducing or controlling HIV viral load in human test subjects; and
    Is designated a "fast track" product candidate by the FDA

PRO 140 has also demonstrated significant advantages over standard-of-care highly active antiretroviral therapy (HAART).

PRO 140 advantages vs. currently approved therapy:

PRO 140

  • No drug resistance in patients on monotherapy for ~24 months
    Viral load suspension in patients on monotherapy for ~24 months
    No serious adverse events (SAEs)
    No serious side effects seen in >200 patients to-date
    No negative impact on immune function


  • 76% of patients have resistance to 1 or more drugs
    Lifelong adherence with only 30% of patients achieving suppressed viral load
    Toxicity ranges from mild to life threatening
    Numerous side effects
    Incomplete recovery of immune function


Ongoing Clinical Trials

CytoDyn has received FDA clearance for and currently has two Phase 3 clinical trials underway. The company's first Phase 3 trial is a pivotal trial with PRO 140 in combination with current standard-of-care antiretroviral therapy (ART) for highly treatment-experienced patients with HIV. This 25-week trial involves only 30 patients with a primary endpoint of just one week of efficacy and the company expects to report primary endpoint results as early as the first quarter of 2017.

The company's other Phase 3 trial is with PRO 140 as a single-agent maintenance therapy in virally suppressed subjects with HIV. This multicenter, open-label trial is enrolling 300 patients prequalified with CCR5-tropic HIV-1 infection who are clinically stable on standard-of-care highly active antiretroviral therapy (HAART). The objective of the trial is to assess the efficacy, safety and tolerability of PRO 140 as a long-acting, single-agent maintenance therapy for the chronic suppression of HIV. Patients enrolled in the trial will be shifted from daily HAART regimens to weekly PRO 140 subcutaneous injections for 48 weeks. This trial protocol is nearly a duplicate of the Phase 2b monotherapy trial, which is ongoing with an extension study that supports a group of patients who have maintained viral suppression for over two years and is continuing.

Additionally, the company has underway a Phase 2 trial to evaluate PRO 140 for Graft vs. Host Disease (GvHD) in a 100-day study involving 60 patients. GvHD is a life-threatening complication for cancer patients undergoing stem cell transplants. This trial will evaluate the safety and efficacy of PRO 140 for prophylaxis of acute GvHD in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) undergoing allogeneic stem-cell transplantation.


The Science of Monoclonal Antibodies

Antibodies are soluble proteins that are produced by the body in response to infections from pathogens like bacteria and viruses. Each individual antibody is synthesized by a unique cell. The secreted protein is shaped like a Y and possesses two identical yet unique binding sites that are specific for a short segment of the offending pathogen.

Vaccines capitalize on the ability of the body to produce antibodies to foreign proteins, also known as antigens, by injecting the antigen of interest with an immune stimulating molecule referred to as an adjuvant. This causes the body to react by producing antibody molecules specific for different parts of the antigen.

Once the antigen is gone from the body the antibody producing cells revert to a dormant state until the antigen is again detected in the body. Then a brisk response ensues and antibody levels rapidly rise in the bloodstream to neutralize the antigen.

Because of the genetic uniqueness among species, antibodies can also be developed that are specific for normal cell proteins. For example, immunizing a mouse with human proteins allows one to produce mouse antibodies that can recognize virtually any human antigen. This has allowed for the development of a variety of diagnostic reagents and therapeutic antibodies specific for human cells.

In the 1980s, a team of scientists won the Nobel Prize in Medicine for developing a technique that fused a common type of tumor cell with a single mouse antibody producing cell. The resulting hybrid cells all secreted the exact same antibody as the original mouse antibody producing cell and thus were called monoclonal antibodies. Since they were part tumor cell, they could be kept virtually forever in a flask. Harvesting the fluid from these cells provided an unlimited amount of highly specific monoclonal antibodies.

Monoclonal antibodies have come to represent one of the fastest expanding opportunities in the biotechnology/pharma sector. The ability to transition from research reagents generated in mice to fully humanized structures suitable for clinical and commercial development has provided some of the most effective and largest selling therapeutics over the last 10 years.



Nader Z. Pourhassan, Ph.D. – President and CEO

Dr. Nader Pourhassan became CytoDyn's managing director of Business Development in June 2011 following his tenure as COO from May 2008 to June 2011. Born in Tehran, Iran, in 1963, Dr. Pourhassan immigrated to the United States in 1977 and became a U.S. citizen in 1991. He received his Bachelor of Science from Utah State University in 1985, his Masters of Science from Brigham Young University in 1990 and his Ph.D. in Mechanical Engineering from the University of Utah in 1998. Prior to joining CytoDyn, Dr. Pourhassan was an instructor of Mechanical Engineering at The Center for Advanced Learning in Oregon, and from 2005 to 2006 was an instructor at Mount Hood Community College. Over the past 20 years, Dr. Pourhassan has also managed a family-owned export/import and manufacturing business.


Denis R. Burger, Ph.D. – Vice Chairman and CSO

Dr. Denis Burger was appointed a CytoDyn director in February 2014, vice chairman in August 2014 and CSO in January 2016. He is a life sciences executive with over 30 years of extensive scientific, operational and financial experience in the biotech industry. As CEO or chairman of several biotechnology companies, Dr. Burger has led numerous corporate financing transactions and public securities offerings and has experience leading R&D, GMP manufacturing and clinical development functional areas. He is currently a director of Aptose Biosciences Inc., a cancer therapeutics, NASDAQ-listed company. Dr. Burger co-founded Trinity Biotech, also a NASDAQ-listed diagnostic company, in June 1992; served as its chairman from June 1992 to May 1995; and is currently lead independent director. Until March 2007, he was chairman and CEO of AVI Biopharma Inc. (now Sarepta Therapeutics), a NASDAQ-listed RNA therapeutics company. He was also a co-founder of Epitope Inc. (now Orasure Technologies, NASDAQ listed), serving as its chairman from 1981 to 1990. Dr. Burger previously held a professorship in the Department of Microbiology and Immunology and Surgery (Surgical Oncology) at the Oregon Health and Sciences University in Portland. Dr. Burger received his undergraduate degree in bacteriology and immunology from the University of California in Berkeley and his Master of Science and Ph.D. degrees in microbiology and immunology from the University of Arizona.


Michael D. Mulholland – CFO, Treasurer and Corporate Secretary

Michael Mulholland brings to CytoDyn more than 25 years of senior level financial leadership for public companies in the business services, retail and manufacturing industries. His broad experience includes strategic planning, corporate finance, including raising debt and equity capital, acquisitions, corporate restructurings, SEC reporting, risk management, investor relations and corporate governance matters. In addition to his financial management experience, Mulholland has also managed IP-asset development for the chemical inventions of a leading European scientific inventor for improving human health, working with IP counsel to evaluate and prosecute domestic and foreign patent applications. Most recently, from 2011-2012, he served as CFO of Nautilus, Inc., a NYSE-listed developer and marketer of fitness equipment. He previously was co-CFO of Corporate Management Advisors, Inc., a private holding company of various businesses and investments, including a majority interest in a publicly held manufacturing company, from 2010 to 2011; vice president of finance of Gevity HR, Inc., a former Nasdaq-listed professional employer organization, from 2008 to 2009; CFO and secretary of Barrett Business Services, Inc., a Nasdaq-listed business services firm, from 1994 to 2008; and executive vice president, CFO and secretary of Sprouse-Reitz Stores Inc., a former publicly held retail company, from 1988 to 1994. He began his career with Deloitte & Touche LLP. Mulholland received a B.S. in accounting and an MBA in finance from the University of Oregon. He is a certified public accountant.


Nitya G. Ray, Ph.D. – Senior VP – Manufacturing

Nitya G. Ray, Ph.D. joined CytoDyn in November, 2015 and is responsible for process development, manufacturing, supply chain and quality. Dr. Ray is an accomplished leader with 30 years of progressive, hands-on experience in diverse manufacturing platforms and product development, including biologics, antibody drug conjugates, engineered tissue therapeutics, small molecule and radiopharmaceutical drugs. Prior to joining CytoDyn, Dr. Ray served as senior vice president of manufacturing at Progenics Pharmaceuticals, Inc. where he was responsible for Process Sciences, Manufacturing and Quality control. Prior to that, he served as director of bioprocess development at Ortec International and held positions of increasing responsibility at Hoffmann-La Roche in the areas of GMP manufacturing and process development for engineered tissue therapeutics and biopharmaceuticals, and at Verax Corporation where he developed process technology for biopharmaceutical manufacturing. Dr. Ray received a Ph.D. and Master of Science in Chemical & Biochemical Engineering from Rutgers University and a Bachelor of Science in Chemical Engineering from Jadavpur University, India.



CytoDyn Inc.
1111 Main St.
Suite 660
Vancouver, WA 98660
Phone: (360) 980-8524

1324 Lexington Ave.
Suite 117
New York, NY 10128
Phone: (212) 418-1217


NetworkNewsWire is a moderator of this board. Please see disclaimer on the NetworkNewsWire website:

1111 Main Street
Suite 660
Vancouver, WA 98660
Telephone: (360) 980-8524
Facsimile: (360) 980-8549
Web Site:


Cytodyn Investor Presentation:

Analyst Coverage:
H.C. Wainwright-
Rodman & Renshaw-

Rising Tide Equity Research-
SeeThruEquity-!cydy-cytodyn/c16os (you will have to enter any email address and password to view reports)

Exchange: OTCQB
Sector: Biotechnology
Industry: Pharmaceutical
Full Time Employees: 5

Share Statistics 11/17/16
Average Volume (3 month): 293.18k
Shares Outstanding: 142.22M
200 day moving average: 0.90
52 week low: 0.61
52 week high: 1.57

CytoDyn Quote

How PRO-140 works
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CYDY News: Current Report Filing (8-k) 08/21/2017 04:06:51 PM
CYDY News: Current Report Filing (8-k) 08/09/2017 04:05:34 PM
CYDY News: Statement of Changes in Beneficial Ownership (4) 07/31/2017 05:41:30 PM
CYDY News: Current Report Filing (8-k) 07/31/2017 05:04:43 PM
CYDY News: Statement of Changes in Beneficial Ownership (4) 07/28/2017 04:09:10 PM
#16418  Sticky Note Taking A Closer Look at Humanized Monoclonal Antibody trding 08/06/17 02:21:17 PM
#16839   As long as they pay at least $10 woodenbear 08/22/17 08:36:33 PM
#16838   Maybe tai med should buy cytodyn! gestalt2 08/22/17 08:33:33 PM
#16837   JPG77- I believe , all HIV patients misiu143 08/22/17 08:18:24 PM
#16836   Ok. This whole conversation about pro140 and izbdjdjx woodenbear 08/22/17 08:05:24 PM
#16835   Me too my wife is a RN. $40-50 123boom 08/22/17 07:12:26 PM
#16834   Very good point! I think I saw somewhere JPG77 08/22/17 07:11:46 PM
#16833   You guys take the cc4 we'll take the 123boom 08/22/17 07:07:45 PM
#16832   "sometimes companies do not charge patients under the JPG77 08/22/17 07:04:35 PM
#16831   No wonder why Fred is here there is 123boom 08/22/17 07:01:57 PM
#16830   Patients can't afford to pay for Ibalizumab but JPG77 08/22/17 06:55:10 PM
#16829   Do you really think there's not going to pearsby09 08/22/17 06:47:05 PM
#16828   Patients can't afford to pay for Ibalizumab but fred198484 08/22/17 06:32:18 PM
#16827   "The company is setting up the program, not JPG77 08/22/17 05:50:12 PM
#16826   The company is setting up the program, not pearsby09 08/22/17 05:46:16 PM
#16825   The company is setting up a program where JPG77 08/22/17 04:48:11 PM
#16824   Exactly. However don't forget, the acquirer of pearsby09 08/22/17 04:37:40 PM
#16823   You again are really working hard to find gestalt2 08/22/17 04:24:46 PM
#16822   I'm not sure if you are American or trding 08/22/17 04:08:25 PM
#16821   Fred,- yes , with IM injection patients misiu143 08/22/17 04:05:26 PM
#16820   There has been so much dialogue, speculation, discussions, pearsby09 08/22/17 04:03:12 PM
#16819   Misiu is right - I will remind you fred198484 08/22/17 04:01:55 PM
#16818   just for fun, here is a sequence of gestalt2 08/22/17 03:24:35 PM
#16817   I agree ,....( Fred will tell you that misiu143 08/22/17 03:20:06 PM
#16816   Yes, and for the small population that are trding 08/22/17 03:12:11 PM
#16815   In the states you can trade it on trding 08/22/17 03:06:00 PM
#16814   Ibalizumab is ONLY adjunct , they don't misiu143 08/22/17 03:01:36 PM
#16813   It might be ok idk. 123boom 08/22/17 02:41:03 PM
#16812   Toronto michelinvests 08/22/17 02:40:07 PM
#16811   What kind of sketchy exchange is that on? 123boom 08/22/17 02:38:42 PM
#16810   FDA more than once mentioned they want to michelinvests 08/22/17 02:38:20 PM
#16809   I’d love to see this chart become a michelinvests 08/22/17 02:34:10 PM
#16808   We are actually all on the same team fred198484 08/22/17 01:18:08 PM
#16807   I might have a naive view of this gestalt2 08/22/17 01:04:07 PM
#16806   Agreed on both counts, but the FDA has BlackDoggie 08/22/17 12:50:13 PM
#16805   What you suggest makes complete sense to us fred198484 08/22/17 12:45:19 PM
#16804   But Ibalizumab is a better drug than PRO trding 08/22/17 12:43:52 PM
#16803   I'm sure that you're correct here about typical BlackDoggie 08/22/17 12:37:04 PM
#16802   Agree 100%, company will be sold by year Axe99 08/22/17 12:34:18 PM
#16801   Big ask off level II? Let's roll... 123boom 08/22/17 12:34:04 PM
#16800   I am bullish on Combo approval (80/20 at pearsby09 08/22/17 12:10:31 PM
#16799   A label expansion typically requires some additional testing, fred198484 08/22/17 12:09:24 PM
#16798   Most importantly....the entire value of this company is pearsby09 08/22/17 12:08:15 PM
#16797   You said you were bullish on combo fred198484 08/22/17 12:06:50 PM
#16796   I don't know why you sent me that pearsby09 08/22/17 12:03:15 PM
#16795   Hello ? Label expansion. buckysherm 08/22/17 11:58:34 AM
#16794   The phase III combo trial is a multidrug fred198484 08/22/17 11:55:52 AM
#16793   This company is as good as sold! When Grip it and Sip It 08/22/17 11:47:23 AM
#16792   Hi Saltz. Yes, I am more Bullish pearsby09 08/22/17 11:31:48 AM
#16791   I think that it absolutely does, but it's BlackDoggie 08/22/17 10:31:55 AM
#16790   Doesn't yesterday's PR potentially lend more credence to TheBioTechG 08/22/17 10:27:14 AM